Arcus Biosciences Sells Equity to Gilead Under Section 4(a)(2)
Company Announcements

Arcus Biosciences Sells Equity to Gilead Under Section 4(a)(2)

Arcus Biosciences Inc (RCUS) has released an update to notify the public and investors about the unregistered sales of equity securities.

The Gilead Financing details referenced earlier pertain to shares sold to Gilead under Section 4(a)(2) of the Securities Act of 1933. The transaction was made with an accredited investor entity.

For further insights into RCUS stock, check out TipRanks’ Stock Analysis page.

For a comprehensive understanding of the announcement, you can read the full document here.

Related Articles
TheFlyArcus Biosciences price target lowered to $35 from $40 at Morgan Stanley
TheFlyArcus Biosciences price target lowered to $43 from $70 at BTIG
TheFlyArcus Biosciences says Taiho exercises option for quemliclustat
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!